Our history

Advanced Oncotherapy plc was created in 2012, but our history goes back much further and is closely linked to the formation and achievements of ADAM SA in Geneva, Switzerland. Learn about our key milestones, the people who have contributed to the development and position of the Company at the forefront of proton therapy technology and about our most recent advances.


Creation of CareCapital, a company focused on developing, owning and leasing healthcare properties to healthcare operators, primarily in the private sector.


IPO of CareCapital on the AIM market.


Foundation of ADAM (Application of Detectors and Accelerators to Medicine), as a spin-off from CERN (the European Organisation for Nuclear Research). The ADAM team, led by Alberto Colussi and Professor Ugo Amaldi, has designed and built the first unit of a linear accelerator for treating cancer, known as LIGHT (Linac Image Guided Hadron Technology).


The Large Hadron Collider (LHC), the world’s largest and most powerful particle accelerator, is turned on. ADAM scientists involved in the project; ADAM's future Executive Chairman integral to its development and management.


CareCapital name changed to Advanced Oncotherapy to reflect the demerger of the property development business and the realignment of the Company's strategy with the aim of capitalising on opportunities in the fields of cancer diagnosis and cancer treatment. This laid the foundations for what Advanced Oncotherapy is today.


Step change in Advanced Oncotherapy's activities with the acquisition of ADAM. A number of key appointments were made amongst the executive, non-executive and medical advisory board. Letters of intent secured for the supply of LIGHT machines.


Supply agreements with Global IT leader ICT, ScandiNova, VDL and Toshiba. Exclusivity agreement with SUNY Upstate Medical University Hospital, NY.


Harley Street lease with The Howard de Walden Estate for the UK's first proton therapy centre using the LIGHT System and operator agreement with Circle Health for the Harley Street site. Progress in technical developments. Distribution agreement with Sinophi Healthcare. Sale of non-core assets.


Key Board and executive appointments in London and Geneva. Technological progress on the LIGHT system, with delivery and successful integration of the proton source and RFQ, plus delivery and high power testing of linac accelerating modules. Industrialisation agreement with Thales for full commercial roll-out of the LIGHT system. A £24m financing facility agreed with Metric Capital Partners LLP for the development of Harley Street; a £10m subscription by the Board, senior management and MK Trust and an associated open offer, which raised gross proceeds of £3.4m. Granting of planning permission for Harley Street. Sale negotiations in UK, USA, Europe, Asia and Middle East; ending of agreement with Sinophi Healthcare.

Who we are

We are leaders in the next generation of proton systems which do not require a cyclotron or synchrotron. We develop cost effective treatments which are clinically superior to those currently available.

Read more


Our strategy is to provide wider and cost-effective access to radiation treatment through a ground-breaking proton therapy system with superior clinical benefits for cancer patients.

Read more

Leadership Team

Our team is made up of highly skilled professionals who have a wide range of experience in their field.

Read more

Corporate governance

Advanced Oncotherapy is committed to the highest standards of corporate governance, business integrity and professionalism. The Directors recognise the importance of sound corporate governance.

Read more


We have a strong foundation of core company values which underpin everything we do.

Read more


Our board brings entrepreneurial, commercial and financial leadership.

Read more


Their expertise and experience are unmatched. Combined they have over 100 years in radiation oncology and over 45 years of treating patients with proton therapy from around the world.

Read more


Interviews highlighting the depth and range of experience with Advanced Oncotherapy.

Read more